Clinical Trial Update: Safety and Tolerability of AAV8 Delivery of a Broadly Neutralizing Antibody in Adults Living With HIV: a Phase 1, Dose-escalation Trial [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study assessing safety and tolerability of AAV8-delivered broadly neutralizing antibody in adults with HIV who have controlled viremia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• AAV8-delivered broadly neutralizing HIV antibody

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV-1 Infected Adults With Controlled Viremia | Phase 1 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-10-25